Credit Deterioration at Medical Institutions and Economic Support for Business Partners
First written in FY2016. 16 of 33 entries say "Mitigated", first in FY2018-Q1. Latest entry: FY2026.
Ship Healthcare Holdings moved to the "Worse" side of this theme in 2025, 1 year before the typical company in this theme (2026).
3 other companies' latest entry also says "Worsened".
- FY2026WorsenedAnnual report
「日本メディカルアライアンス㈱ ¥6,318 million ¥7,176 million」
The guaranteed amount for companies other than consolidated companies increased from ¥6,318 million at the end of the previous fiscal year to ¥7,176 million, expanding the credit and financial support exposure to business partners. - 2026-05-12WorsenedEarnings
「“Allowance for doubtful accounts” increased by ¥2,572 million」
The allowance for doubtful accounts increased by ¥2,572 million from the end of the previous fiscal year, expanding credit and collection-related exposure. - FY2026-H1WorsenedAnnual report
「日本メディカルアライアンス㈱ ¥6,318 million ¥6,515 million」
The guaranteed amount for 日本メディカルアライアンス㈱ increased from ¥6,318 million at the end of the previous consolidated fiscal year to ¥6,515 million, expanding the credit and financial support exposure to business partners. - FY2025WorsenedAnnual report
「日本メディカルアライアンス㈱ ¥5,697 million ¥6,318 million」
The guaranteed amount for companies other than consolidated companies increased from ¥5,697 million at the end of the previous consolidated fiscal year to ¥6,318 million, expanding the credit and financial support exposure to business partners. - FY2025-H1MitigatedAnnual report
「日本メディカルアライアンス㈱ ¥5,697 million ¥5,558 million」
The guaranteed amount for 日本メディカルアライアンス㈱ decreased from ¥5,697 million at the end of the previous consolidated fiscal year to ¥5,558 million, reducing the credit and financial support exposure. - FY2024-Q3MitigatedAnnual report
「日本メディカルアライアンス㈱ ¥6,793 million ¥6,241 million」
The guaranteed amount for 日本メディカルアライアンス㈱ decreased from ¥6,793 million at the end of the previous consolidated fiscal year to ¥6,241 million, reducing the credit and financial support exposure. - FY2024-Q2MitigatedAnnual report
「日本メディカルアライアンス㈱ ¥6,793 million ¥6,189 million」
The guaranteed amount for 日本メディカルアライアンス㈱ decreased from ¥6,793 million at the end of the previous consolidated fiscal year to ¥6,189 million, reducing the credit and financial support exposure. - FY2024-Q1MitigatedAnnual report
「日本メディカルアライアンス㈱ ¥6,793 million ¥6,503 million」
The guaranteed amount for 日本メディカルアライアンス㈱ decreased from ¥6,793 million at the end of the previous consolidated fiscal year to ¥6,503 million, reducing the credit and financial support exposure. - FY2023-Q3MitigatedAnnual report
「日本メディカルアライアンス㈱ ¥7,405 million ¥6,453 million」
The guaranteed amount for 日本メディカルアライアンス㈱ decreased from ¥7,405 million at the end of the previous consolidated fiscal year to ¥6,453 million, reducing the credit and financial support exposure to business partners. - FY2023-Q2MitigatedAnnual report
「日本メディカルアライアンス㈱ ¥7,405 million ¥5,762 million」
The guaranteed amount for 日本メディカルアライアンス㈱ decreased from ¥7,405 million at the end of the previous fiscal year to ¥5,762 million, reducing the credit and financial support exposure. - FY2023-Q1MitigatedAnnual report
「日本メディカルアライアンス㈱ ¥7,405 million ¥6,973 million」
The guaranteed amount for 日本メディカルアライアンス㈱ decreased from ¥7,405 million at the end of the previous fiscal year to ¥6,973 million, reducing the credit and financial support exposure to business partners. - FY2022WorsenedAnnual report
「日本メディカルアライアンス㈱ ¥7,034 million ¥7,405 million」
The guaranteed amount for companies other than consolidated companies increased from ¥7,034 million at the end of the previous fiscal year to ¥7,405 million, expanding the credit and financial support exposure to business partners. - FY2022-Q3MitigatedAnnual report
「日本メディカルアライアンス㈱ ¥7,034 million ¥6,750 million」
The guaranteed amount for 日本メディカルアライアンス㈱ decreased from ¥7,034 million at the end of the previous consolidated fiscal year to ¥6,750 million, reducing the credit and financial support exposure to business partners. - FY2022-Q1MitigatedAnnual report
「日本メディカルアライアンス㈱ ¥7,034 million ¥6,196 million」
The guaranteed amount for 日本メディカルアライアンス㈱ decreased from ¥7,034 million at the end of the previous consolidated fiscal year to ¥6,196 million, reducing the credit and financial support exposure to business partners. - FY2021WorsenedAnnual report
「日本メディカルアライアンス㈱ ¥6,917 million ¥7,034 million」
The guaranteed amount for companies other than consolidated companies increased from ¥6,917 million at the end of the previous consolidated fiscal year to ¥7,034 million, expanding the credit and financial support exposure to business partners. - FY2021-Q3WorsenedAnnual report
「日本メディカルアライアンス㈱ ¥6,917 million ¥7,826 million」
The guaranteed amount for 日本メディカルアライアンス㈱ increased from ¥6,917 million at the end of the previous consolidated fiscal year to ¥7,826 million, expanding the credit and financial support exposure to business partners. - FY2021-Q2MitigatedAnnual report
「日本メディカルアライアンス㈱ ¥6,917 million ¥6,421 million」
The guaranteed amount for 日本メディカルアライアンス㈱ decreased from ¥6,917 million at the end of the previous consolidated fiscal year to ¥6,421 million, reducing the credit and financial support exposure. - FY2021-Q1MitigatedAnnual report
「日本メディカルアライアンス㈱ ¥6,917 million ¥5,906 million」
The guaranteed amount for 日本メディカルアライアンス㈱ decreased from ¥6,917 million at the end of the previous consolidated fiscal year to ¥5,906 million, reducing the credit and financial support exposure. - FY2020WorsenedAnnual report
「日本メディカルアライアンス㈱ ¥6,798 million ¥6,917 million / Okkar Thiri Co.,Ltd. － million ¥1,196 million / Snow Everest Co.,Ltd. － million ¥724 million」
The guaranteed amount for 日本メディカルアライアンス increased from ¥6,798 million at the end of the previous consolidated fiscal year to ¥6,917 million. In addition, newly disclosed letters of intent concerning management guidance for Okkar Thiri and Snow Everest amounted to ¥1,196 million and ¥724 million, respectively, expanding the financial support exposure to business partners. - FY2020-Q3WorsenedAnnual report
「日本メディカルアライアンス㈱ ¥6,798 million ¥7,765 million / Okkar Thiri Co.,Ltd. － million ¥1,577 million / Snow Everest Co.,Ltd. － million ¥897 million」
The guaranteed amount for 日本メディカルアライアンス increased from ¥6,798 million at the end of the previous consolidated fiscal year to ¥7,765 million. The amounts of the letters of intent concerning management guidance were ¥1,577 million for Okkar Thiri and ¥897 million for Snow Everest, expanding the financial support exposure to business partners. - FY2020-Q2WorsenedAnnual report
「日本メディカルアライアンス㈱ ¥6,798 million ¥6,483 million / Okkar Thiri Co.,Ltd. － million ¥2,028 million / Snow Everest Co.,Ltd. － million ¥1,079 million」
The guaranteed amount for 日本メディカルアライアンス decreased from ¥6,798 million to ¥6,483 million, while the amounts of the newly disclosed letters of intent concerning management guidance for Okkar Thiri and Snow Everest were ¥2,028 million and ¥1,079 million, respectively, expanding the financial support exposure. - FY2020-Q1Decrease in guarantees and issuance of new letters of intentAnnual report
「日本メディカルアライアンス㈱ ¥6,798 million ¥6,356 million / Okkar Thiri Co.,Ltd. ¥1,120 million / Snow Everest Co.,Ltd. ¥290 million」
The guaranteed amount for 日本メディカルアライアンス㈱ decreased from ¥6,798 million at the end of the previous consolidated fiscal year to ¥6,356 million. Meanwhile, newly disclosed letters of intent concerning management guidance were issued for Okkar Thiri Co.,Ltd. and Snow Everest Co.,Ltd. - FY2019-Q3MitigatedAnnual report
「日本メディカルアライアンス㈱ ¥7,290 million ¥7,090 million」
The guaranteed amount for companies other than consolidated companies decreased from ¥7,290 million at the end of the previous consolidated fiscal year to ¥7,090 million, resulting in a modest reduction in credit and financial support exposure. - FY2019-Q2MitigatedAnnual report
「日本メディカルアライアンス㈱ ¥7,290 million ¥5,715 million」
The guaranteed amount for companies other than consolidated companies decreased from ¥7,290 million at the end of the previous consolidated fiscal year to ¥5,715 million, further reducing the credit and financial support exposure to business partners. - FY2019-Q1MitigatedAnnual report
「日本メディカルアライアンス㈱ ¥7,290 million ¥6,661 million」
The guaranteed amount for companies other than consolidated companies decreased from ¥7,290 million at the end of the previous consolidated fiscal year to ¥6,661 million, reducing the credit and financial support exposure to business partners. - FY2018MitigatedAnnual report
「日本メディカルアライアンス㈱ ¥6,870 million ¥7,290 million」
The guaranteed amount for companies other than consolidated companies decreased from ¥7,544 million at the time of the previous quarterly report to ¥7,290 million. - FY2018-Q3WorsenedAnnual report
「日本メディカルアライアンス㈱ ¥6,870 million ¥7,544 million」
The guaranteed amount for companies other than consolidated companies increased from ¥6,870 million at the end of the previous consolidated fiscal year to ¥7,544 million, expanding the credit and financial support exposure to business partners. - FY2018-Q2WorsenedAnnual report
「日本メディカルアライアンス㈱ ¥6,870 million ¥6,368 million」
Although the guaranteed amount for companies other than consolidated companies decreased from the end of the previous consolidated fiscal year, it increased from ¥6,144 million at the time of the previous quarterly report to ¥6,368 million. - FY2018-Q1MitigatedAnnual report
「日本メディカルアライアンス㈱ ¥6,870 million ¥6,144 million」
The guaranteed amount for companies other than consolidated companies decreased from ¥6,870 million at the end of the previous consolidated fiscal year to ¥6,144 million. - FY2017-Q3WorsenedAnnual report
「日本メディカルアライアンス㈱ ¥6,792 million」
The guaranteed amount for companies other than consolidated companies was ¥6,792 million, up from ¥6,074 million disclosed in the previous quarter. - FY2017-Q2RestatedAnnual report
「日本メディカルアライアンス㈱ ¥6,074 million」
Guarantees for companies other than consolidated companies continue to be disclosed, with the guaranteed amount standing at ¥6,074 million. - FY2017-Q1RestatedAnnual report
「The company provides guarantees for borrowings and trade payables of companies other than consolidated companies.」
Guarantees for companies other than consolidated companies have been disclosed, with the guaranteed amount standing at ¥6,054 million. - FY2016First statedAnnual report
「Some medical institutions and others are considered to face potential bad-debt risks due to the impact of recent healthcare system reforms and changes in the external environment.」
In addition to bad-debt risks at medical institutions, financial support through loans and deferred-payment instalment sales could increase the funding burden. Of trade receivables and loans, 7.8% is attributable to specific major business partners.